A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis

针对瓜氨酸化蛋白的一类抗体能够预防类风湿性关节炎

阅读:11
作者:Yibo He ,Changrong Ge ,Àlex Moreno-Giró ,Bingze Xu ,Christian M Beusch ,Katalin Sandor ,Jie Su ,Lei Cheng ,Erik Lönnblom ,Christina Lundqvist ,Linda M Slot ,Dongmei Tong ,Vilma Urbonaviciute ,Bibo Liang ,Taotao Li ,Gonzalo Fernandez Lahore ,Mike Aoun ,Vivianne Malmström ,Theo Rispens ,Patrik Ernfors ,Camilla I Svensson ,Hans Ulrich Scherer ,René E M Toes ,Inger Gjertsson ,Olov Ekwall ,Roman A Zubarev ,Rikard Holmdahl

Abstract

Although elevated levels of anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis (RA), the in vivo functions of these antibodies remain unclear. Here, we have expressed monoclonal ACPAs derived from patients with RA, and analyzed their functions in mice, as well as their specificities. None of the ACPAs showed arthritogenicity nor induced pain-associated behavior in mice. However, one of the antibodies, clone E4, protected mice from antibody-induced arthritis. E4 showed a binding pattern restricted to skin, macrophages and dendritic cells in lymphoid tissue, and cartilage derived from mouse and human arthritic joints. Proteomic analysis confirmed that E4 strongly binds to macrophages and certain RA synovial fluid proteins such as α-enolase. The protective effect of E4 was epitope-specific and dependent on the interaction between E4-citrullinated α-enolase immune complexes with FCGR2B on macrophages, resulting in increased IL-10 secretion and reduced osteoclastogenesis. These findings suggest that a subset of ACPAs have therapeutic potential in RA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。